News
Following today’s release of DFS’ figures for the 52 weeks ending 29 June 2025; Matt Walton, senior retail analyst at ...
Localising and automating supply chains will allow companies to mitigate the impact of tariffs and minimise resulting costs.
10d
Just Auto on MSNGovernment subsidies drive China’s vehicle market up – GlobalData"Government subsidies drive China’s vehicle market up – GlobalData" was originally created and published by Just Auto, a ...
9d
Just Auto on MSNWestern Europe’s car market down 1% in first half of year – GlobalData"Western Europe’s car market down 1% in first half of year – GlobalData" was originally created and published by Just Auto, a ...
2d
GlobalData on MSNCaranx Medical’s AI TAVI-TAVR software gains FDA approvalThe US Food and Drug Administration (FDA) has cleared Caranx Medical’s TAVIPILOT Soft, an artificial intelligence (AI)-based guide software for use during Transcatheter Aortic Valve Implantation (TAVI ...
Experian (EXPN), Barratt Redrow (BTRW), B&M European Value (BME), GlobalData (DATA), Robert Walters (RWA), Mobico (MCG), ...
(Alliance News) - GlobalData PLC on Tuesday said its process for move to London's Main Market away from the AIM Market is underway, as it highlighted continued investment in Growth Transformation Plan ...
Walmart and its banking partner Mastercard have created a new payment system for international money transfers, data ...
Artificial intelligence, robotics and the Internet of Things (IoT) are no longer futuristic concepts—they are reshaping how consumer brands operate, engage and grow. As these technologies move from ...
6d
Air Force Technology on MSNDSET 2025: a tour of military simulation training systemsMany companies gathered in Bristol to showcase military simulation systems at the Defence Simulation, Education, and Training exhibition.
2d
Private Banker International on MSNKirkland & Ellis leads North American M&A legal Advisers in H1 2025Kirkland & Ellis has topped the legal adviser ranking in mergers and acquisitions (M&A) by value and volume in North America ...
13d
Clinical Trials Arena on MSNNovartis’ Cosentyx shows no benefit in Phase III GCA trialNovartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results